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Abstract
Breast cancer is a multifactorial disease. A spectrum of internal and external factors contributes to the disease
promotion such as a genetic predisposition, chronic inflammatory processes, exposure to toxic compounds,
abundant stress factors, a shift-worker job, etc. The cumulative effects lead to high incidence of breast cancer in
populations worldwide. Breast cancer in the USA is currently registered with the highest incidence rates amongst
all cancer related patient cohorts. Currently applied diagnostic approaches are frequently unable to recognise early
stages in tumour development that impairs individual outcomes. Early diagnosis has been demonstrated to be
highly beneficial for significantly enhanced therapy efficacy and possibly full recovery. Actual paper shows that the
elaboration of an integrative diagnostic approach combining several levels of examinations creates a robust
platform for the reliable risk assessment, targeted preventive measures and more effective treatments tailored to
the person in the overall task of breast cancer management. The levels of examinations are proposed, and
innovative technological approaches are described in the paper. The absolute necessity to create individual patient
profiles and extended medical records is justified for the utilising by routine medical services. Expert
recommendations are provided to promote further developments in the field.
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With the respect to the statistical data presented by the
World Health Organisation [1], cancer is a leading cause
of death worldwide, accounting for 7.6 million deaths
(around 13% of all deaths) as registered in 2008 and per-
manently increasing over 13 million as projected for
2030. Economic factors play a role, since about 70% of
all cancer deaths in 2008 occurred in low- and middle-
income countries. The most fatal types of cancer are
listed below in the decreasing order (deaths per year):
❖ lung (1.37 million deaths)
❖ stomach (736 000 deaths)
❖ liver (695 000 deaths)
❖ colorectal (608 000 deaths)
❖ breast (458 000 deaths)
❖ cervical cancer (275 000 deaths).
Breast cancer is the most common cause of cancer-
related death among women
Hence in the USA, the highest cancer related incidence
rates are currently registered for the breast cancer patient
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cohorts [2] – see Figure 1A. The combating and treating
measures such as induced population screening by mam-
mography and application of adjuvant therapies, keep
breast cancer mortality mostly unchanged or even persist-
ently declined over last ten years – see Figure 1B. How-
ever, the incidence of breast cancer continually increases
worldwide during the past three decades. According to
the statistical data published by the National Cancer Insti-
tute in the USA [3], the estimated new cases and deaths
from breast cancer in the United States in 2012 are (in
thousand cases)
❖ New cases: 226.870 (female); 2.190 (male)
❖ Deaths: 39.510 (female); 410 (male)
Breast Cancer Metastatic Disease (BCMD) is currently
incurable: challenges of diagnostics and treatment
Breast Cancer Metastatic Disease (BCMD)
Diagnostic approaches routinely applied in medical prac-
tice are frequently unable to recognise early stages in
breast cancer development that impair the outcome. At
the time of diagnosis, a great portion of patients with
breast cancer have locally advanced and/or distant meta-
static disease. It is estimated that about 6% of breast
cancer patients demonstrate a clinical picture of meta-
static disease already at the time of diagnosis. Further
20% to 50% patients with primary breast cancer will de-
velop metastatic disease despite the standardised
treatments approached [4]. BCMD (stage IV) is the most
advanced form of breast cancer. Once breast cancer has
turned metastatic, the disease is recognised as the incur-
able one: the 5-year survival barrier will be reached by
only 26% of patients treated for the BCMD.
Distant metastases
The lion’s share of about 90% of deaths in the overall
breast cancer related mortality is caused by the distant
metastases. Breast cancer spreads metastasis predomin-
antly into lymph nodes, bone, lung, skin, brain, and liver
[5], wherefrom only lymph nodes are considered as non-
Figure 1 A. Estimated cancer incidence in USA in 2009; B. Cancer related mortality as registered in USA in 2009; data adapted from [2].
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distance metastases. With the poorest prognosis of ap-
proximately 80% mortality rate within first 12 months of
diagnosis, brain metastases represent a devastating cat-
egory of BCMD. Brain metastases are prevalent in hor-
mone receptor negative but HER2-overexpressing
subgroups and are typical for 30% of all HER2+ BCMD
[4]. The particular challenge in treating brain metastases
is created by the limited permeability of the blood–brain
barrier for chemotherapeutics, the use of which, further,
leads to brain inflammatory response with extensive
gliosis surrounding the metastases. The treated brain
metastases are further provoked for high proliferation
but minimal apoptosis demonstrating unsatisfactory
effects of current treatments. Therefore, innovative diag-
nostic approaches to trace the micrometastases and
therapeutic approaches aimed at stabilising and eliminat-
ing distant metastases – both do not exist yet being
emergent in the nearest future.
Diagnosis of BCMD
Advanced imaging technologies are currently considered
as being the most appropriate tool to diagnose BCMD, to
detect the primary lesions and to trace the distance metas-
tases over the whole body (whole-body imaging). To
currently well recognised technologies belong multi-
dimensional and multimodal ones: CT, MRI, PET, SPECT,
and ultrasound; PET and the combined PET/CT is the key
tool for the whole-body scanning. However, there are
some substantial clinical deficits which imaging technolo-
gies suffer from in pinpointing the disease type [4].
RT-PCR Small-size metastases in lymph nodes may be
detected by amplification of the smallest amounts of
transcripts produced by BCMD biomarkers such as CK19
and others. The greatest limitation of the methodology is
false-positive results potentially received due to the mixed
cell populations which cannot be completely excluded by
the resection. A conclusion might be also doubtful, due to
untargeted biomarkers, particularly for heterogeneous
tumours that is, indeed, the frequent case [4].
Disseminated and circulating tumour cells Individual
tumour cells in bone marrow and blood stream cannot
be detected by conventional imaging. For poor progno-
sis, more relevant and better detectable are tumour cells
disseminated in bone marrow (DTC), compared to cir-
culating tumour cells (CTC) in peripheral blood [6].
However, the invasiveness of the DTC sampling hardly
finds the acceptance by patients. Consequently, blood
tests for the CTC detection is a promising approach, in
particular for the diagnosing of BCMD which de-
monstrates the most abundant representation of tumour
cells in blood followed by high rates of CTC in prostate
cancer, in contrast to significantly lower levels of CTC
spread by other tumour types [7]. However, this ap-
proach suffers from substantial technological limitations
such as an extremely low frequency of CTC in a blood
stream that makes the tool almost useless for the detec-
tion of BCMD at its early stages [8]. Consequently, the
reliable results’ interpretation is currently possible only
for the advanced stages of the tumour progression /
BCMD and for patients with poor prognosis [9]. The
promising diagnostic approach might be the molecular
characterisation of CTC as the predictor of the tumour
invasiveness and therapy response [6].
Treatment of BCMD
Currently applied strategies for the treatment of BCMD
make use of systemic cytotoxic agents that lead to severe
and irreversible organic side-effects significantly decreas-
ing the life quality of the patients followed by a limited
long-term success in metastasis suppression: only 1-3%
of patients remain long-term disease-free after BCMD
treatments [4]. Although new agents like paclitaxel,
trastuzumab and aromatase inhibitors improve the
short-term survival rates (up to 36 months), the thera-
peutic goals remain at the level of survival prolongation
and symptoms palliation.
The experts are fully consent with the fact that novel
drug targets should be elaborated for a successful
BCMD treatment tailored to the patient. In this context,
molecular defects driving clinical onset of BCMD, begin-
ning with the initiation step to the micrometastasis pro-
gression till BCMD virulence, create the robust panel of
the drug target candidates [10]. Recent reports from ani-
mal models of BCMD treatments keep a hope in poten-
tial improvements which, however, are not going to
happen for the patients tomorrow.
Breast cancer risk assessment
“Molecular portrait“ and more
Early detection of the tumour has been demonstrated to
be highly beneficial for significantly enhanced therapy ef-
ficacy. An accurate navigation by predictive diagnosis
may lead to full recovery after surgical resection [11].
Furthermore, a detection of individual predisposition to
breast cancer represents the optimal way how the path-
ology may be diagnosed before its clinical onset and de-
velopment of the fatal BCMD. Breast cancer risk
assessment is currently extensively under consideration.
The major problem, however, is linked to the multifac-
torial nature of the disease. Consequently, the list of
parameters with impacts for the disease onset and pro-
gression at the individual level, i.e. personal risk factors
differ significantly from patient to patient. This consider-
ation leads to better understanding, why the “across-the
-board” treatment of breast cancer is frequently ineffect-
ive, and the pathology specific “portrait” should be
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created at the individual level. On this, any biological
manifestation is operated and controlled at the molecu-
lar level. Therefore, the “portrait featuring” originates
from the specific set-up of individual biomolecules and
corresponding interaction among relevant pathways at
molecular, subcellular and cellular levels. This “molecu-
lar portrait” creates an individual condition for the
disease predisposition and promotion, which is recognis-
able and modifiable through individual pathology spe-
cific “molecular patterns”. For the clinically relevant and
issue sensitive interpretation, the informational input
from the “molecular patterns” should be combined with
complementary technologies such as medical imaging,
which altogether contribute to the creation of the indi-
vidual “patient profiles” as the robust platform for
personalised healthcare services. The expected outcomes
are conducive to more effective population screening,
prevention early in childhood, identification of persons
at-risk, stratification of patients for the optimal therapy
planning, prediction and reduction of adverse drug-drug
or drug-disease interactions.
Innate immune system as a putative origin of mammary
gland
Resulting from the accumulated data from knowledge
about morphological particularities, cell composition
bioinformatics research, a new concept to the evolution-
ary origin of mammary gland has been presented
suggesting that the gland’s initial function was the
provision of innate immunity later evolving into its
current nutritional role [12]. Indeed, immune cells are
abundant in both physiologic and pathologic mammary
tissue. The immune cells are implicated in the develop-
ment of human mammary glands: leucocytic infiltrates
have been detected in normal pubertal and adult gland
tissue [12,13]. Furthermore, bone marrow depletion
leads to blocked ductal elongation in murine experimen-
tal models of mammary gland development. Taking to-
gether the above listed facts, the decisive role of the
immune cells in physiology of mammary glands is get-
ting obvious. This fascinating discovery opens great
perspectives for innovative diagnostic tools based on a
minimally invasive blood test platform and might be
highly beneficial for novel drug targets of increased effi-
cacy in breast cancer treatments.
Immune cells and inflammation as tumour modifiers in
breast: expression patterns of activated leucocytes
collaborative with neoplastic cells under chronic
inflammatory condition?
The paradoxical role of leucocytes as protectors, re-
gulators, modifiers and causal players in the breast car-
cinogenesis becomes extensively discussed in current
literatures. Both innate (myeloid) and adaptive (lymphoid)
leucocyte types have been demonstrated as breast cancer
modifiers [14]. Doubtless cytotoxic T-lymphocytes have a
function in constraining tumour developments that is evi-
dent, in particular, for the tumours of viral origin [15]. On
the other side, the chronic activation of leucocytes
paradoxically play a role in initiating / potentiating
carcinogenesis: infiltrating B-lymphocytes have been
reported to represent the predominant lymphocytic popu-
lation in premalignant breast tissue [14]. Further, B-cells
represent the predominant lymphocytes during early
breast cancer, whereas infiltrating T-lymphocytes are more
extensive in higher graded ductal in situ and invasive
breast carcinomas [16,17].
What is the mechanism of the tumour promotion by
inflammatory leucocytes? The key-point is their unique
plasticity in producing protein products and bioactive
mediators essential for all stages in the tumour progres-
sion such as reactive oxygen species, tissue-remodelling
(e.g. metalloproteinases) angiogenesis prompting (e.g.
VEGF) protein-complexes [18,19]. Certainly, this enor-
mous capacity is conditioned by the stage specific
expression patterns in activated leucocytes. Under the
chronic inflammatory condition the expression patterns
of infiltrating leucocytes obviously become collaborative
with those of neoplastic cells. An excellent example is
provided by tissue-remodelling proteins secreted from
activated leucocytes. An altered metalloproteinase activ-
ity impacts directly the mammary gland physiology dur-
ing morphogenesis, hormonal cycle and lactation, as
well as during inflammatory acute / chronic process,
cancer pre-lesions, tumour progression, and metastatic
disease. Besides other cell types in the population, in-
flammatory and immune cells are the major producers
of metalloproteinases [20]. Although the impacts of the
metalloproteinase activities are well acknowledged for
mammary glands physiology and pathophysiology, the
relevance of the metalloproteinase patterns as the breast
cancer modifiers in the context of inflammation and im-
mune cells represents won its recognition only recently
in the scientific world [21].
Molecular patterns in activated leucocytes as the
minimally invasive diagnostic tool for breast cancer risk
assessment
Pursuing the above conclusions, it is getting obvious that
the molecular/expressional patterns in orchestrated
leucocytes are activated strictly in accordance to the pre-
cancerous / cancer stage. If detected in correlation with
the corresponding disease initiation and progression
stage, these patterns in activated leucocytes might be of
high relevance for the diagnostic and treatment
purposes. This consideration leads to the idea of creating
a minimally invasive approach for breast cancer risk as-
sessment based on ex vivo blood tests by examination of
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the specific molecular/expressional patterns in circulat-
ing leucocytes.
The OVERALL TASK: Multimodal diagnostic approaches,
disease specific biomarker-patterns, individual patient
profiles, creation of medical records and treatments
tailored to the person
Paradigm change from a delayed approach after clinical
onset of the pathology to predictive diagnostics followed
by targeted prevention and individualised treatment
algorithms tailored to the patient, creates an innovative
concept for advanced healthcare that is costs effective
[22]. Particularly attractive are non-invasive diagnostic
approaches considering disease-specific alterations in mo-
lecular patterns of blood cells and serum in predisposed
individuals before clinically disease onset [11,23-29].
Identification of pathology-specific biomarker-patterns
increases the specificity and predictive power of analytical
approach. Combination of patterns at subcellular, intracel-
lular and extracellular levels contributes to high sensitivity
and specificity of the analysis. Mathematic modelling
of patient-specific profiles allows for an accurate pre-
diction of individual predisposition before the path-
ology is manifested. Integrative medical approach by
predictive diagnostics, targeted prevention and personalised
treatments is considered as the medicine of the future. The
expected outcomes are conducive to more effective popula-
tion screening, prevention early in life, identification of per-
sons at-risk, stratification of patients for the optimal
therapy planning, prediction and reduction of adverse
drug-drug or drug-disease interactions relying on emerging
technologies, such as medical imaging, pharmacogenetics,
*omics, disease modelling, individual patient profiles, inte-
grative medical records, etc.
Technological design: integrative concept
The integrative concept of the technological design is
summarised in Figure 2. An optimal sep-up of
stakeholders and a high quality of the performance of
single operating steps (sub-projects) guarantee for a
discovery and qualification of innovative diagnostic ap-
proaches and valid drug targets to be successfully
implemented in clinical practice. The crucial step in the
overall experimental scheme is a well-established patient
model that reflects the clinical condition(s). Large-scaled
studies to identify novel diagnostic biomarkers and
therapeutic targets followed by validation, standardisa-
tion and application procedures are essential in breast
cancer research.
Creation of medical records
Creation of medical records is the crucial step in the
overall task of prediction, precise disease diagnosing and
successful application of the treatment algorithms
tailored to the person. Medical record should carry an
integrative character presenting and evaluating disease
relevant data at any applicable level of the examination /
detection. The major points to be obligatory involved in
the medical records related to the breast cancer are
summarised below:
– Sur/name
– Date of birth / Age
– Ethnicity [30]
– Menopausal status [30]
– Menstrual cycle (duration, regularity etc.)
– History of pregnancies and childbirth
– Last date, type and result of past individual cancer
screening (mammography, pap smear etc.)
– Breast / Cancer familial background (as described
elsewhere)
– Histological statement for malignant tumours /
benign indication
– Drug history: alcohol, nicotine etc.
– Medication history (i.e. steroids, blood pressure
medication, anti-inflammatory medication etc.)
– For malignant tumours: evaluation of combined
results by medical imaging, categorisation of the
carcinoma (invasive lobular, ductal carcinoma in




























Figure 2 Moving from basic research to clinical implementation: basic steps in creating the robust diagnostic platform and treatments
tailored to the person.
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type of metastases, receptor status, HER2, etc.)
molecular subtypes (luminal a & b, basal, etc.)
– For benign patients: acknowledged breast cancer risk
factors (childless, lack of breast feeding, breast
trauma / inflammations / biopsy, etc.) [30]
– Frequent co-morbidities (Diabetes type 2,
cardiovascular disease, depression) [31,32]
– Environmental particularities (geographic factors,
environmental toxicity, such as an excess of heavy
metals and toxic compounds as described elsewhere)
– Inactive life-style and overweight (body mass index)
that influence the pathology development and
outcomes [31,32]
– Sleep disorders as the predisposition and the cause
of cancer [33]
– Detectable stress factors with acknowledged impacts
for BC development such as a shift-worker’s job [34]
– Breast / Cancer specific molecular patterns in blood
(as discussed later in text)
– Metastasis specific biomarkers in blood (medical
imaging and CTC detection as discussed above)
Construction of diagnostic windows for minimally
invasive breast cancer risk assessment based on immune
cells profiling
This multimodal approach utilises a combination of con-
ventional analytical methodology for a creation of the
pathology specific biomarker patterns at complementary
levels of detection, namely
 Medical imaging (primary tumour, distanced
metastasis)
 Subcellular / molecular imaging by “comet assay”
DNA analysis (risk assessment for general tumour
predisposition)
 Clinical differential proteomics as the “gene hunting”
approach for pathology specific molecular patterns
in blood cells
 Blood metabolomics for quantification of disease
relevant metabolite patterns
 Quantitative analysis of enzymatic activities in blood
plasma
 others
followed by mathematical modelling of pathology-
specific profiles.
Here we demonstrate the analytical procedure for two
levels of detection, namely molecular imaging by quanti-
tative “comet assay” and clinical proteomics.
Subcellular / molecular imaging by “comet assay”-
analysis
The “comet assay” provides a simple and effective method
for evaluation of DNA damage and DNA-repair capacity in
single cells such as leucocytes. The principle of the assay is
based upon the ability of DNA fragments to migrate out of
the cell under the influence of an electric field. An evalu-
ation of the “comet” tail shape and DNA fragments migra-
tion pattern allows for assessment of DNA damage and
repair capacity. DNA-damage is assigned to 4 classes
based on the visual aspect of the comets, considering the
extent of DNA migration as published earlier [35]. Comets
with a bright head and almost no tail are classified as class
I with minimal DNA damage. Comets with no visible head
and a long diffuse tail are classified as class IV (severely
damaged/apoptotic cells). Comets with intermediate
characteristics are assigned to classes II and III dependent
on the ratio R = T/r, where T is a length of comet´ s tail
and r is a radius of comet´ s head. The characteristic value
of R for class 1 is 1 (T ≈ r) and for class 4 is ∞ (r = 0).
Comets with values 1<R<3 are classified as class 2 (see the
original image). Comet classes are demonstrated with the
image provided in the Figure 3.
Subcellular / molecular imaging by quantitative “comet
assay” has characterised the breast cancer patients as
follows:
➢ Increased damage to DNA
➢ Debilitated apoptotic reaction towards increased DNA
damage
➢ Pathology specific comet patterns
➢ Impact of hormonal status on specificity of comet
patterns among breast cancer patients
➢ Characteristic windows of comet patterns that may
be utilised for breast cancer risk assessment – both
positive (at high-risk) and negative (at low-risk)
prediction.
I II III IV 
Figure 3 Image of the characteristic classes of comets
(representing intact and damaged DNA) are shown ex vivo for
circulating leucocytes [35].
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An example of the diagnostic windows for breast
cancer risk assessment using comet classes I (intact
DNA) and IV (apoptotic) is demonstrated in Figure 4
[36]. The constructed diagnostic windows clearly dis-
tinguish between tumour and benign patients and
may be considered for the practical application in dif-
ferential molecular diagnostics. For this diagnostic
tool two parameters in medical records are of par-
ticular importance, namely the age and menopausal
status.
Clinical differential proteomics as the promissing tool for
breast cancer risk assessment
Protein mapping in circulating leucocytes of breast cancer
patients
The protein mapping performed in our recent project
resulted in altogether 158 protein spots distinguished;
the overall spots correspond to 74 proteins the amino
acid sequences of which have been consequently identi-
fied utilising the analytical technology of MALDI-TOF –
see Figure 5 [11]. The identified proteins are listed in the
Table 1.
Concomitantly to the protein identification, the func-
tional classification has been performed. The list of func-
tional groups is provided with the separate Table 2.
Breast cancer specific expression patterns as potential
candidates for the predictive-diagnostic biomarker panel
The expression profiles under the cancer condition have
been quantified versus the control group with benign
and no breast tumours detected [11]. The resulting in-
formation is provided in Table 1. In accordance to statis-
tical analysis, altogether four categories have been built-
up as follows: A. statistically significant alterations in the
expression profiles under the cancer condition compared
to the control group; B. statistically non-significant
alterations in the expression profiles under the cancer
condition compared to the control group; C. expression
levels altered individually with highly heterogeneous ex-
pression profiles within the patient group versus stable
expression levels within the control group; D similar
expression-profiles within both patient and control
groups of comparison. Here detected pathology specific
patterns might be further considered for the creation of
A C
B D
Figure 4 Diagrams estimating a predictive power of the comet-fractions (comet class I and IV), further utilised in the construction of
diagnostic windows for breast cancer risk assessment (A, B and C); according to the diagnosis, the recruited patients are grouped as
follows: pre-menopausal women with benign alterations in breast tissue (G1); post-menopausal women with benign alterations in
breast tissue (G2); invasive lobular & ductal carcinomas in pre-menopausal women (G3); invasive lobular & ductal carcinomas in post-
menopausal women (G4); data taken from [36]. Obviously, the diagnostic windows with the comet class IV patterns can be effective only
when the hormonal status is considered as one of the selection parameters for subgrouping the patients and concomitant utilisation of the
analytical approach proposed by this study.
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the biomarker panel of high predictive power in diag-
nosing of the breast cancer development.
Group-specific versus individual therapy response: potential
prognostic tool by proteomic blood tests?
As it is summarised in Table 1, the reaction towards the
standardised radiotherapy has been quantified at the level
of the protein expression rates in circulating leucocytes.
The resulting statistical analysis demonstrated following
patterns: 14 proteins were significantly suppressed and 4
proteins were significantly induced in all patients tested.
In contrast, further 4 proteins were individually (group-
non-significantly) suppressed and 2 proteins individually
(group-non-significantly) induced. However, for the
absolute majority (50) of the proteins measured strictly
individual post-therapeutic regulation (up- / down or un-
changed) was monitored. These findings motivates a cre-
ation of the “follow-up” projects to learn more about
“molecular signature” of the patient beneficial therapy
response as the potential prognostic tool.
What do we learn by the function of proteins involved in
the breast cancer specific expression alterations in blood?
Below listed groups (see Table 2) have been created
according to the function(s) of individual proteins identified







































































Figure 5 Protein mapping in circulating leucocytes of breast cancer patients; first-dimensional separation was performed in
immobilised pH gradient (IPG) strips (Bio-Rad, USA) in the range of IP 4–7. Following first-dimensional separation, the extruded IPG-strips
were equilibrated in gel equilibration buffer I (50 mM Tris–HCl, 6 M urea, 30% glycerol, 2% SDS, 1% DTT), followed by equilibration in buffer II (50
mM Tris–HCl, 6 M urea, 30% glycerol, 2% SDS and 260 mM iodacetamide) for 10 min before loading them onto polyacrylamide gels (12% SDS-
PAGE) for the second-dimensional resolution in Mini-PROTEAN 3 (Bio-Rad). Altogether, 74 proteins were consequently identified by MALDI-TOF
analysis; data taken from [11].
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Table 1 Protein profile alterations in breast cancer and under radiotherapy
Spot number Access
number
Accession name Protein name Functional group
number
Classification, references relevant for





CATEGORY A: significantly (T≤0.1) altered expression profiles in patients versus controls
112-116 P04040 CATA_HUMAN Catalase 5, 9, 10, 11, 14, 18,
19, 20, 21




Individual reaction ⬆ ⬇
157 P07737 PROF1_HUMAN Profilin-1 1, 2, 11, 19, 20, 21 Microfilamental network cell-migration
related protein [11,43-48]
homogeneous
upregulation ⬆ 4,0x T=0,02
homogeneous
suppression ⬇ T=0,05
23-27 P63261 ACTG_HUMAN Actin, cytoplasmic 2
(Gamma-actin)
1, 2, 11, 14, 18, 19,
20, 21
Microfilamental network protein [49-52] homogeneous suppression
⬇ 2x T=0,02
Individual reaction ⬆ ⬇
124 P27797 CRTC_HUMAN Calreticulin precursor
CRP55
2, 11, 12, 17, 18,
19, 20, 21
Endoplasmic reticulum calcium-storage





Individual reaction ⬆ ➜
⬇
155 P30043 BLVRB_HUMAN Flavin reductase, NADHP-
dependent reductase




70-74 P13645 K1C10_HUMAN Keratin, type I
cytoskeletal 10
1, 2, 11, 18, 19,
20, 21




136 O00299 CLIC1_HUMAN Chloride intracellular
channel protein 1




⬇ 2,5x T=0,04 Individual reaction ⬆ ⬇
156 P08238 HS90B_HUMAN Heat shock protein HSP
90-beta
12, 13, 14, 11, 17,
18, 19, 20, 21




141 P13489 RINI_HUMAN Placental ribonuclease
inhibitor
3, 9, 12, 14, 17, 20,
21




82 P62937 PPIA_HUMAN Peptidyl-prolyl cis-trans
isomerase A
4, 11, 12, 14, 17,
19, 20, 21




Individual reaction ⬆ ➜
⬇
28 not identified protein highly upregulated in
several MKs T=0,06
Individual reaction ⬆ ⬇
53 not identified protein highly upregulated in
several MKs T=0,06
Individual reaction ⬆ ⬇




⬇ 2x T=0,09 Individual reaction ⬆ ➜
⬇
62, 85 93-95 P00915 CAH1_HUMAN Carbonic anhydrase I 5, 11, 18 19, 20,
21
Energy metabolism related protein [98-104] ⬇ 2x T=0,10 Individual reaction ⬆ ⬇








135 P49411 EFTU_HUMAN Elongation factor Tu,
mitochondrial precursor
7, 20 Mitochondrial protein synthesis machinery,




Individual reaction ⬆ ➜
⬇
45-46 P52566 GDIS_HUMAN Rho GDP-dissociation
inhibitor 2 (Rho GDIß)
1, 2, 11, 12, 14, 17,
19, 20, 21
LyDGI plays a role in the onset of apoptosis
and cell migration [11,112-116]
homogeneous
upregulation ⬆ T=0,1


















Table 1 Protein profile alterations in breast cancer and under radiotherapy (Continued)
148 P63104 1433Z_HUMAN 14-3-3 protein zeta/delta
(protein kinase C inhibitor)
11, 12, 14, 17, 18,
19, 20, 21






67 P06702 S10A9_HUMAN Protein S100-A9,
Calgranulin




⬆ 2,5x T=0,11 Individual reaction ⬆ ➜
⬇
110 not identified protein highly upregulated in
several MKsT=0,11
Individual reaction ⬆ ⬇
123 P07237 PDIA1_HUMAN Protein disulfide-
isomerase precursor, PDI
4, 14, 9, 17, 18, 20,
21
Stress-related protein modification enzyme
[60,128-131]
⬇ 2,5x T=0,12 Individual reaction ⬆ ⬇
104 not identified protein highly upregulated in
several MKsT=0,12
Individual reaction ⬆ ⬇
CATEGORY B: non-significantly altered expression profiles in patients versus controls
131 P78371 TCPB_HUMAN T-complex protein 1
subunit beta




19-21, 39 P60709 ACTB_HUMAN Actin, cytoplasmic 1
(Beta-actin)
1, 2, 11, 14, 18, 19,
20, 21
Microfilamental network protein [11] slightly increased ⬆
1,5x T=0,16
Individual reaction ⬆ ➜
⬇
97 P60174 TPIS_HUMAN Triosephosphate
isomerase




Individual reaction ⬆ ⬇









80 P05109 S10A8_HUMAN Protein S100-A8,
Calgranulin
2, 11, 14, 18, 19,
20, 21
Ca2+-dependent cell-migration / tumour
related protein [11,120-127]
homogeneous ⬆ 2,0x T=0,24 Individual suppression ⬇
37 P47756 CAPZB_HUMAN F-actin-capping protein
subunit beta (CapZ beta)
1, 2, 11, 14, 18, 19,
20, 21
Microfilamental network protein [142-145] slightly increased ⬆ T=0,2 Individual reaction ⬆ ⬇
137 P30041 PRDX6_HUMAN Peroxiredoxin-6 9, 10, 11, 14, 17,
18, 19, 20, 21
Multifuctional anti-oxidant, defence, tumour-
invasion and metastases related protein
[146-150]
slightly increased T=0,2 Individual reaction ⬆ ⬇
9-11 P02679 FIBG_HUMAN Fibrinogen gamma chain 11, 17, 19, 20, 21 Microfilamental network cell-migration
related protein [151-157]
homogeneous ⬆ 1,5x T=0,24 Individual reaction ⬆ ➜
⬇
130 P10809 CH60_HUMAN 60 kDa heat shock protein 4, 5, 7, 11, 13, 17,
19, 20, 21






36 Q5U077 Q5U077_HUMAN L-lactate dehydrogenase B 5, 7, 11, 19, 20,
21
Energy metabolism related protein
[134,167-172]
slightly increased ⬆ 1,5x Individual reaction ⬆ ⬇
122 Q96C61 Q96C61_HUMAN FLNA protein 1, 2, 11, 14, 19,
20, 21
Filamin A - actin binding protein has essential
role in intercellular junctions [173-178]
homogeneous ⬆ 1,5x Individual reaction ⬆ ⬇
151 P07996 TSP1_HUMAN Thrombospondin-1
precursor
2, 15, 11, 14, 17,
19, 20, 21
The matricellular protein regulating cell
adhesion and motility during tissue






















Table 1 Protein profile alterations in breast cancer and under radiotherapy (Continued)
CATEGORY C: individual group-heterogeneous expression profiles in patients versus homogeneous one in controls
86,87 P00918 CAH2_HUMAN Carbonic anhydrase II 5, 11, 18, 19, 20,
21
Energy metabolism related protein
[98-100,103,104,190,191]
Individual heterogeneous Individual reaction ⬆ ⬇
103 P02675 FIBB_HUMAN Fibrinogen beta chain
precursor
11, 17, 19, 20, 21 Microfilamental network cell-migration
related protein [151-157]
Individual heterogeneous Individual reaction ⬆ ➜
⬇
117-120 O75083 WDR1_HUMAN WD repeat-containing
protein 1
4, 12, 11, 14, 20 Cell-cycle and proteolytic machinery
related protein [189,192]
Individual heterogeneous Individual reaction ⬆ ➜
⬇
126 P28331 NUAM_HUMAN NADH-ubiquinone
oxidoreductase 75 kDa
5, 7, 9, 11, 14, 19,
20, 21
Mitochondrial energy metabolism related
protein [193-197]
highly heterogeneous Individual reaction ⬆ ⬇
127 P08133 ANXA6_HUMAN Annexin A6 (P70) 2, 8, 11, 14, 16, 17,
19, 20, 21
Membrane architecture and signalling
protein [127,198-201]
Individual induction Individual induction ⬆
128 P11142 HSP7C_HUMAN Heat shock cognate 71
kDa protein
4, 5, 11, 13, 14, 17,
18, 19, 20, 21
Stress response protein,chaperone, ATPase
[202-206]
Individual heterogeneous Individual reaction ⬆ ➜
⬇
144 Q53XX6 ATPA_HUMAN ATP-synthase, H+
transporting
mitochondrial protein
5, 7, 8, 11, 18, 19,
20, 21
Mitochondrial energy metabolism related
protein [207-212]
Individual heterogeneous Individual reaction ⬆ ⬇
147 P31946 1433B_HUMAN 14-3-3 protein beta/
alpha (protein- kinase-C
inhibitor)
4, 11, 12, 14, 17,
19, 20, 21








highly heterogeneous Individual reaction ⬆ ⬇
CATEGORY D: similar expression-profiles among patients and controls






similar Individual reaction ⬆ ⬇
12,13, 32, 33,
43, 47, 48, 98
P60709 ACTB_HUMAN Actin, cytoplasmic
1 (Beta-actin)
Microfilamental network protein similar Individual reaction ⬆ ⬇
14-15 P68363 TBA1B_HUMAN Tubulin alpha-
chain
Microtubule network protein similar Individual reaction ⬆ ⬇




Mitochondrial energy metabolism related
protein
similar Individual reaction ⬆ ⬇
18 P07437 TBB2_HUMAN Tubulin beta-2
chain
Microfilamental network protein similar Individual reaction ⬆ ➜
⬇




P13645 K1C10_HUMAN Keratin, type I
cytoskeletal 10


















Table 1 Protein profile alterations in breast cancer and under radiotherapy (Continued)
40, 41 P63261 ACTG_HUMAN Actin, cytoplasmic
2 (Gamma-actin)
Microfilamental network protein similar Individual reaction ⬆ ⬇
42 Q6FHP5_HUMAN PHB protein Prohibitin - negative regulator of cell
proliferation and may be a tumor
suppressor. Mutations in PHB have been
linked to sporadic breast cancer.
similar homogeneous
suppression ⬇
49-50 P67936 TPM4_HUMAN Tropomyosin
alpha-4 chain
Microfilamental network protein similar Individual reaction ⬆ ⬇
88 P02768 ALBU_HUMAN Serum albumin Extracellular transport/carrier protein similar Individual reaction ⬆ ⬇
96 P18669 PGAM1_HUMAN Phosphoglycerate
mutase 1
Energy metabolism related protein similar homogeneous
suppression ⬇ T=0,1
99 P00558 PGK1_HUMAN Phosphoglycerate
kinase 1
Energy metabolism related protein similar Individual reaction ⬆ ➜
⬇
100 P68871 HBB_HUMAN Hemoglobin
subunit beta
Oxygen carrier similar Individual reaction ⬆ ⬇
101, 102, 106 P06733 ENOA_HUMAN Alpha-enolase multifunctional glycolytic enzyme similar Individual reaction ⬆ ➜
⬇
107 P14618 KPYM_HUMAN Pyruvate kinase,
isozymes M1/M2
Energy metabolism related protein similar Individual reaction ⬆ ➜
⬇




Signal transduction pathways associated
with endoplasmic reticulum stress
similar homogeneous
suppression ⬇ T=0,1
129 P13796 PLSL_HUMAN Plastin-2 Microfilamental network protein similar homogeneous
suppression ⬇ T=0,02
132 Q53QM2 Q53QM2_HUMAN Hypothetical
protein ACTR3
Currently uncharacterized protein similar homogeneous
suppression ⬇ T=0,1
133 Q6IAT1 Q6IAT1_HUMAN GDI2 protein (GDP
dissociation
inhibitor 2)
Regulatory protein in the functional
cycle and recycling of Rab GTPases







similar Individual reaction ⬆ ⬇
138 P09211 GSTP1_HUMAN Glutathione S-
transferase P (GST
class-pi)




139 P07741 APT_HUMAN Adenine
phosphoribosyl-
transferase
Nucleotide metabolism similar Individual reaction ⬆ ➜
⬇
140 P11021 GRP78_HUMAN 78 kDa glucose-
regulated protein
precursor (GRP 78)



















Table 1 Protein profile alterations in breast cancer and under radiotherapy (Continued)
145 P13716 HEM2_HUMAN Delta-
aminolevulinic
acid dehydratase




146 Q5JQI4 HSP71_HUMAN Heat shock 70 kDa
protein 1A
Stress response protein similar Individual reaction ⬆ ⬇
149 Q06323 PSME1_HUMAN Proteasome
activator complex
subunit 1
The activator binds to proteasome 20S &
enhances peptidase activity, e.g. under
stress conditions
similar Individual reaction ⬆ ⬇
150 P00491 PNPH_HUMAN Purine nucleoside
phosphorylase
Nucleotide- and nucleoside turnover,
detoxification pathway
similar Individual suppression ⬇
153 P12429 ANXA3_HUMAN Annexin A3 Membrane architecture and signalling
protein






Membrane protein, regulation of cell
growth / death via redox-control




Twinfilin-2, Protein tyrosine kinase 9-like,




Annotation to Table 1: 158 spots have been distinguished by protein mapping as stably expressed (i.e. by all members of the group) in circulating leucocytes of the group with breast cancer patients. Altogether 74
proteins have been identified within 158 spots. The protein mapping image is demonstrated in Figure 5. The spot number in the map (Spot number) and corresponding accession number (Access number) and
name (Accession name) received from the SwissProt database is provided in the table together with the name of the identified protein (Protein name) in accordance with the current protein nomenclature. The
column “Classification” provides information about the function(s) currently known for each protein. The corresponding number of the functional group(s) is/are provided in the column “Functional group number”;
the designation of the functional group with the corresponding number can be found in the separate Table 2. The regulation manner (up / down regulation) and the severity of the expression profile alterations under
the cancer condition have been qualified and quantified versus the values in the control group; the resulting information is provided in the column “Profile alterations versus controls”. In accordance to the
expression profile alterations, every mapped protein has been assigned to one of the altogether four CATEGORIES built-up as follows: A = 22 proteins with the statistically significant alterations in the expression
profiles under the cancer condition compared to the control group (T≤0,1); B = 12 with the statistically non-significant alterations in the expression profiles under the cancer condition compared to the control group;
C = 9 proteins with the expression profiles altered individually with highly heterogeneous expression profiles within the patient group versus stable expression levels within the control group; D = 31 proteins with
similar expression-profiles within both patient and control groups of comparison. Further, under the cancer condition, the expression alterations as the reaction towards the applied radiotherapy has been qualified (up
/ down regulation) and quantified as it is summarised for each protein in the column “Alterations under radiotherapy”. The resulting statistics is provided here: 14 proteins homogeneously (group-significantly)
suppressed (⬇ ), 4 proteins homogeneously (group-significantly) induced (⬆ ), 4 proteins individually (group-non-significantly) suppressed (⬇ ), 2 proteins individually (group-non-significantly) induced (⬆ ), 33


















leucocytes (see Table 1). The literature sources relevant for
the issue are listed in the Table 1 respectively to the func-
tional groups. What do we learn from the exercise?
➢ According to the content summarised in the Table 2,
it is evident that the breast cancer specific protein
profiles affect a spectrum of the central biological
activities in and of the cell.
➢ The multifactorial impacts of the disease are evident.
➢ Certainly there are effective interactions among
individual functional groups: several proteins are
involved and play a (key) role at least in two but
frequently in a much higher number of the
functional groups listed.
➢ All the proteins with expression rates altered under
the breast cancer condition as described in this
article, have been reported to stay in a kind of
relation to cancer / breast cancer / metastatic
activity. Moreover, some of the combinations of the
proteins presented here have been already reported
in relation to breast/cancer.
➢ However, the particular value of this article is in the
systematic overview of the integrative panel of
proteins/functional groups involved in the breast
cancer specific molecular patterns in blood cells.
➢ Furthermore, the tool is obviously of high importance
in favour of non-invasive prediction of breast cancer,
since only very few literature sources could be found
for breast cancer blood biomarker/patterns.
Personalised treatments of the manifested breast cancer:
where are we now?
During the last years several biomarkers as well as molecu-
lar factors have made their way into clinical routine. Exten-
sive translational research, new mathematical models and
computer-based analysis resulted in validated markers that
allow personalised decision making for each individual pa-
tient already nowadays. Below we summarise the actualities
and factors that have recently been shown to provide add-
itional prognostic or predictive information and can finally
spare ineffective or even harmful treatments (e.g. chemo-
therapy) and promote approaches tailored to the patient.
Table 2 Systematic overview of the integrative panel of proteins/functional groups involved in the breast cancer
specific molecular patterns in blood cells
Nr. Functional group Relevance for breast cancer
in tissue [reference]
Relevance for breast
cancer in blood [reference]
1 microfilamental network-associated and cytoskeletal-assembly
proteins
[48,223,224] [11]
2 cell motility, migration & adhesion [225-227] [11]
3 nucleoside / nucleotide turnover & metabolism [228,229]
4 protein metabolism (regulatory protein-synthesis & protein-
modification enzymes, chaperons)
[230,231] [231]
5 energy metabolism [232-236] [232,236]
6 vitamin metabolism [237,238]
7 mitochondrial proteins [239-241] [239,241]
8 channels, membrane-architecture and intercellular-junction proteins [242]
9 anti-oxidant defence / red-ox control [243-246] [245]
10 detoxification proteins [247]
11 stress-response / -protection related protein [75,248-250]
12 cell-cycle machinery proteins [251-253]
13 heat-shock proteins [254-258]
14 apoptosis-related proteins / protection against apoptosis [259-261] [262,263]
15 tissue-remodelling enzymes [21,264-268]
16 extra-cellular transport & carrier-proteins [258,269,270]
17 signal-transduction proteins / signalling pathways [271-274]
18 longevity / ageing related proteins [275-278]
19 inflammation related / anti-inflammatory proteins [14,21,279]
20 (breast) cancer related inhibitor / promoter see references to individual proteins listed
in the Table 1
21 cancer invasion and regulator of metastases formation see references to individual proteins listed
in Table 1
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Clinicopathological factors, such as the histological sub-
type, tumour grade as well as the expression of the
receptors for oestrogen, progesterone and HER2 belong to
the most established evidence for making decisions over
individualised therapeutic approaches. Therefrom, the ex-
pression levels of oestrogen receptor and HER2 are cur-
rently the best known predictive and prognostic biomarkers
for individualised breast cancer therapy [280]. Increased ex-
pression rates of HER2 is the valid biomarker for an un-
favourable prognosis in breast cancer management
[281,282]. Furthermore, retrospective studies revealed a
functional link between the level of HER2 expression and
an individual patient response towards endocrine therapy
and sensitivity to taxanes and anthracyclines [283-285].
However, the highest impact of HER2 in the clinical prac-
tice is its predictive and prognostic value indicating a re-
sponse to trastuzumab and pertuzumab as well as to
lapatinib (an inhibitor of the tyrosine kinase domain within
HER1 and HER2 sequences) [286-288].
Further, a potential clinical utilisation of novel biomarkers
dealing with the enzymatic complexes of cell proliferation,
such as ki67 and uPA/PAI-1, is on the horizon. Hence, an
elevated expression of ki67 is a potent marker for aggressive
tumour types and a consequently poor prognosis [289,290].
Several studies demonstrated an association of ki67 expres-
sional level with the quality of patient response towards
chemotherapy and endocrine therapy [291,292]. Conse-
quently, ki67 has been included into the St. Gallen Consen-
sus Recommendations to stratify breast tumours according
to the level of proliferation [293]. In primary breast cancer,
independent prognostic factors uPA/PAI-1 indicates a level
of the tumour invasion and metastatic disease that is of par-
ticular value for treatments of the node-negative breast
cancer [294,295]. Both factors have reached highest level of
evidence (LOI-1) and have been recommended for the clas-
sification of the groups of risk in making decisions for
treatments of the node-negative breast cancer [296,297].
The central role in creating an individual risk profile
receives the computer assistance. For example, Adjuvant!
Online is an internet-based algorithm aiming at prediction
of the recurrence free survival and total survival over 10
years [298]. This programme takes into consideration the
best established clinical and pathology-specific contributing
risk factors such as tumour size, nodal involvement, hist-
ology, hormone receptor status and age in combination
with co-morbidities registered. Adjuvant!Online may be po-
tentially utilised to prognose individual risks and benefits of
endocrine therapy and / or variants of chemotherapy
regimes proposed individually for the patients [299-301].
An alternative programme is PREDICT+ for the efficacy
prediction based on individual HER2 parameters and hor-
mone status [302-304].
Gene expression profiles receive more and more rec-
ognition in the overall breast cancer management
including typification, prediction, prognosis and therapy
regiments. Based on the common gene expression
patterns, the molecular breast cancer subtypes have been
grouped into five classes, namely Luminal-A, Luminal-B,
Basal-like, ErbB2-like and normal-like ones [305,306].
Therefrom, each intrinsic breast cancer subtype is
characterised by an individual prognostic relevance,
patterns of the metastatic disease and typical response to
single therapy approaches [307-309]. Consequently,
these intrinsic subtypes have been included into the St.
Gallen Consensus Therapy Recommendations [293]. For
the first time in the history of breast cancer manage-
ment, the Consensus Expert Panel decides on the indi-
vidualisation of the adjuvant therapy considering the
molecular patterns as follows:
➢ sole endocrine therapy in Luminal-A-cancers
➢ endocrine therapy in combination with
chemotherapy in Luminal-B cancers
➢ sole chemotherapy in Basal-Like subtypes, and
➢ chemotherapy in combination with anti-HER2
-treatment in ErbB2-like breast cancer.
Further, there are commercially available multi-gene
assays that may be used to prognose individual recur-
rence scores and may assist in making decisions on sin-
gle treatment regiments. The most common are
MammaPrint and Oncotype DX assays [310,311]. There-
with, MammaPrint is able to distinguish breast cancer
patients with a good prognosis to avoid unnecessary and
even harmful treatments [312,313]. In contrast, the iden-
tified cohort of patients with a poor prognosis are more
likely to achieve beneficial results by neo-adjuvant
chemotherapy [314]. Oncotype DX is developed for
patients with hormone receptor positive tumours under-
going endocrine treatment with tamoxifen. Therefore, this
test identifies patients with a low risk of the tumour recur-
rence, who would not benefit from additionally applied
adjuvant chemotherapy [315]. An add-value of the
Oncotype DX application as evident for the node-positive
disease, since patients with high tumour-recurrence scores
may well benefit from anthracycline-based chemotherapy
[316]. Both assays are currently under the prospective
study in the MINDACT trial (MammaPrint) and
TAILORx trial (Oncotype DX) to validate their overall
clinical utility for the personalised application of adjuvant
chemotherapeutic approaches [317,318].
Recommendations and outlook
Diagnosis and treatments of breast cancer metastasis
disease (BCMD) are extremely challenging that prompts
a development of emerging technologies for the effective
prevention of breast cancer. Therefore, the overall task
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is formulated as the integrative medical approach of the
multimodal diagnostics, disease specific biomarker-
patterns, individual patient profiles, creation of medical
records and treatments tailored to the person. In this
context, a minimally invasive breast cancer risk assess-
ment appears to be a plausible approach for early / pre-
dictive diagnosis of cancer pre-stages and targeted
treatments before the clinical onset of BCMD.
The multimodal diagnostiscs represents a model-based
examination procedure with several levels of examin-
ation resulting in the extended patient profiles and
medical records which should obligatory include an
interview with the patient / a questionnaire form filled
in for pathology relevant information, medical imaging,
laboratory diagnostics and evaluation of pathology rele-
vant risk factors. For the laboratory diagnostics it is
highly recommended to use valid blood tests for the de-
tection of the stage specific molecular patterns in
activated leucocytes as explained above.
For the application of adjuvant therapeutic approaches,
our ethical responsibility requests a carefully created
balance between risks and benefits to justify the individu-
ally made decisions. A predictive genetic testing should be
fixed by law to determine effective treatment options by
evaluating efficacy, e.g. in the case of cytochrome P450
CYP2D6 genotyping to decide on tamoxifen application
tailored to the patient.
Innovative medical records should be, further, developed
to cover current deficits in the above listed clinical and
laboratory expertise and to create individual patient
profiles utilising mathematical modelling and integrative
bioinformatics.
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